argenx SE (ETR:1AE)

Market Cap	37.53B
Revenue (ttm)	2.66B
Net Income (ttm)	1.09B
Shares Out	n/a
EPS (ttm)	15.96
PE Ratio	34.42
Forward PE	32.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Average Volume	29
Open	606.80
Previous Close	618.80
Day's Range	601.00 - 606.80
52-Week Range	601.00 - 662.20
Beta	n/a
RSI	38.52
Earnings Date	Oct 30, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 1,599
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 1AE

Financial Performance

Financial numbers in USD